Therefore, we postulate that a pre-treatment targeting NFKB1 could increase the efficacy of TRAIL and MSC-TRAIL-mediated inhibition through CD133+ CSC sensitization in NSCLC. Here, TNFSF10 is linked to non-small cell lung carcinoma.